Pharmacological background of EGFR targeting
作者： L. Castillo , M.C. Etienne-Grimaldi , J.L. Fischel , P. Formento , N. Magné
关键词:
摘要: Epidermal growth factor receptor (EGFR) signaling pathways play a key role in the regulation of cell proliferation, survival and differentiation. As consequence, EGFR is one best studied ligand-receptor system specific inhibition approaches are currently among most promising advanced clinical setting. Monoclonal antibodies (mAbs) tyrosine kinase inhibitors (TKIs) have been developed, which C225 (Cetuximab) ZD1839 (Iressa), respectively, advanced. The aim present review was not to cover field inhibitors, but compare at experimental levels different points governing actions mAbs TKIs. In addition, combinations conventional chemotherapies with targeting drugs, as well resistance mechanisms targeting, reviewed.
oup.com
oxfordjournals.org
oupjournals.org参考文章(66)
Sarah B. Noonberg, Christopher C. Benz, Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs. ,vol. 59, pp. 753- 767 ,(2000) , 10.2165/00003495-200059040-00003
Y Yarden, The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. European Journal of Cancer. ,vol. 37, pp. 3- 8 ,(2001) , 10.1016/S0959-8049(01)00230-1
Moscatello Dk, Wong Aj, Wong My, McDanel H, Montgomery Rb, Sundareshan P, Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene. ,vol. 13, pp. 85- 96 ,(1996)
Jonathan M. Bock, Shyh-Min Huang, Paul M. Harari, Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research. ,vol. 59, pp. 1935- 1940 ,(1999)
Paul Carter, Improving the efficacy of antibody-based cancer therapies Nature Reviews Cancer. ,vol. 1, pp. 118- 129 ,(2001) , 10.1038/35101072
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
Oliver Bögler, Motoo Nagane, Frank Coufal, H-J. Su Huang, H-J. Su Huang, Hong Lin, Webster K. Cavenee, A Common Mutant Epidermal Growth Factor Receptor Confers Enhanced Tumorigenicity on Human Glioblastoma Cells by Increasing Proliferation and Reducing Apoptosis Cancer Research. ,vol. 56, pp. 5079- 5086 ,(1996)
Z Fan, Y Lu, X Wu, J Mendelsohn, Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. Journal of Biological Chemistry. ,vol. 269, pp. 27595- 27602 ,(1994) , 10.1016/S0021-9258(18)47026-3
Zhen Fan, Hideo Masui, John Mendelsohn, Jose Baselga, Antitumor Effect of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies plus cis-Diamminedichloroplatinum on Well Established A431 Cell Xenografts Cancer Research. ,vol. 53, pp. 4637- 4642 ,(1993)
Julie M. Cherrington, Randall E. Schreck, Dirk B. Mendel, Jean Cui, James G. Christensen, Emily Chan, Chris Yang, James Wei, Luna Liu, Li Sun, Xueyan Wang, High Levels of HER-2 Expression Alter the Ability of Epidermal Growth Factor Receptor (EGFR) Family Tyrosine Kinase Inhibitors to Inhibit EGFR Phosphorylation in Vivo Clinical Cancer Research. ,vol. 7, pp. 4230- 4238 ,(2001)